DaVita Inc. Common Stock (DVA)
Stock · NYSE · Health Care
$187.16as of 10/16/2026
Price chart
Active signals
DVA Signal Track Record
How signals performed across all stocks →What DVA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 34 | +0.9% | 53% | September 17, 2026 |
| Bollinger Band Breakout | 26 | +5.2% | 69% | September 14, 2026 |
| Bollinger Band Breakdown | 22 | +1.1% | 55% | August 5, 2026 |
| 200-Day Moving Average TouchActive now | 11 | -4.4% | 36% | July 23, 2025 |
| Any 20-session window (baseline) | +1.0% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About DVA
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other phys…
- Sector
- Health Care
- Industry
- Misc Health and Biotechnology Services
- Employees
- 78,000
- Website
- www.davita.com/
Fundamentals
- 1-day range
- $182.56$189.25
- Market cap
- $11.53B
- P/E (trailing)
- 13.65
- P/E (forward)
- 11.03
- EPS (trailing)
- $12.21
- Dividend yield
- —
- Beta
- 0.88
- Avg. volume
- 753.9K
How DaVita Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 11, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
DaVita Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DVADaVita Inc. Common Stock$187.31▼ 0.98%Market cap $11.53BP/E 13.65$101$247.49
- FMSFresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share)$22.17▲ 0.18%Market cap $13.46BP/E 10.86$34.57$47.54
- SHCSotera Health Company Common Stock$17.89▼ 1.00%Market cap $5.39BP/E 31.54$13.09$19.85
- PGNYProgyny Inc. Common Stock$26.86▼ 2.17%Market cap $2.37BP/E 25.32$16.1$33.07
- AGLagilon health inc. Common Stock$85.12▼ 3.76%Market cap $1.45BP/E —$7.48$133.04
- VMDViemed Healthcare Inc. Common Shares$9.48▼ 2.77%Market cap $362.60MP/E 25.72$6.05$12.61
- PARKPark Dental Partners Inc. Common Stock$18.95▼ 1.33%Market cap $96.71MP/E —$9.53$26.79
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DVA DaVita Inc. Common Stock | $11.53B | 13.65 | $187.31 | ▼ 0.98% | $101$247.49 |
| FMS Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) | $13.46B | 10.86 | $22.17 | ▲ 0.18% | $34.57$47.54 |
| SHC Sotera Health Company Common Stock | $5.39B | 31.54 | $17.89 | ▼ 1.00% | $13.09$19.85 |
| PGNY Progyny Inc. Common Stock | $2.37B | 25.32 | $26.86 | ▼ 2.17% | $16.1$33.07 |
| AGL agilon health inc. Common Stock | $1.45B | — | $85.12 | ▼ 3.76% | $7.48$133.04 |
| VMD Viemed Healthcare Inc. Common Shares | $362.60M | 25.72 | $9.48 | ▼ 2.77% | $6.05$12.61 |
| PARK Park Dental Partners Inc. Common Stock | $96.71M | — | $18.95 | ▼ 1.33% | $9.53$26.79 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Why DaVita HealthCare (DVA) Outpaced the Stock Market TodayYahoo · 10/9/2026
- DaVita: After A 25% Drop, The Buyback Machine Is Cheap AgainSeekingAlpha · 10/9/2026
- Here's Why You Should Retain DaVita Stock in Your Portfolio for NowYahoo · 10/9/2026
- DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare EarlyYahoo · 10/8/2026
- Michael Burry Warns Anthropic’s Valuation Could Buy 78 Profitable S&P 500 Companies: ‘Fun Game in Times Like These’Benzinga · 10/8/2026
- Strength Seen in Option Care (OPCH): Can Its 32.7% Jump Turn into More Strength?Yahoo · 10/7/2026
- DaVita HealthCare (DVA) Laps the Stock Market: Here's WhyYahoo · 10/2/2026
- 3 Cash-Producing Stocks with Open QuestionsYahoo · 9/30/2026
Insider Activity
Insider Actions →- David Paul Maughan · September 22, 2026 · Tax Withholding7.5K @ $182.34
- Dennis W. Pullin · August 15, 2026 · Grant278
- Gregory J. Moore · August 15, 2026 · Grant278
- Jason M. Hollar · August 15, 2026 · Grant278
- Pamela M. Arway · August 15, 2026 · Grant278
- Adam H. Schechter · August 15, 2026 · Grant278
- Wendy Lee Schoppert · August 15, 2026 · Grant278
- Phyllis R. Yale · August 15, 2026 · Grant278
- Barbara J. Desoer · August 15, 2026 · Grant278
- BERKSHIRE HATHAWAY INC · July 31, 2026 · Sale183.0K @ $199.55
- Javier Rodriguez · June 16, 2026 · Sale39.4K @ $209.28
- Kathleen Alyce Waters · June 15, 2026 · Sale6.5K @ $209.17
- Kathleen Alyce Waters · June 15, 2026 · Sale8.9K @ $207.84
- Javier Rodriguez · June 15, 2026 · Sale30.0K @ $209.5
- Phyllis R. Yale · May 26, 2026 · Gift5.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 61.29M
- Total value held
- $9.05B
- Institutional holders
- 571
- Unknown30.10M
- Unknown2.77M
- Unknown2.18M
- Unknown1.67M
- Unknown1.47M
- Unknown1.35M
- Unknown1.15M
- Unknown1.11M
- Unknown939.8K
- Unknown931.1K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
DaVita (DVA) Discussed as Potentially Undervalued Cash Producer
Recent articles highlight DaVita as a cash-producing stock that may be undervalued relative to its earnings power. The company has outperformed the broader market recently, with one analysis noting a 58% gain. While the stock is trading near its 52-week low, analysts maintain a higher average price target, suggesting a gap between current price and long-term expectations.
DaVita (DVA) Discussed as Potentially Undervalued Cash Producer. Recent articles highlight DaVita as a cash-producing stock that may be undervalued relative to its earnings power. The company has outperformed the broader market recently, with one analysis noting a 58% gain. While the stock is trading near its 52-week low, analysts maintain a higher average price target, suggesting a gap between current price and long-term expectations.